Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity

Abstract

One of the primary challenges in developing effective therapies for malignant tumors is the specific targeting of a heterogeneous cancer cell population within the tumor. The cancerous tumor is made up of a variety of distinct cells with specialized receptors and proteins that could potentially be viable targets for drugs. In addition, the diverse signals from the local microenvironment may also contribute to the induction of tumor growth and metastasis. Collectively, these factors must be strategically studied and targeted in order to develop an effective treatment protocol. Targeted multimodal approaches need to be strategically studied in order to develop a treatment protocol that is successful in controlling tumor growth and preventing metastatic burden. Breast cancer, in particular, presents a unique problem because of the variety of subtypes of cancer that can arise and the multiple drug targets that could be exploited. For example, the tumor stage and subtypes often dictate the appropriate treatment regimen. Alternate multimodal therapies should consider the importance of time-dependent drug administration, as well as targeting the local and systemic tumor environment. Many reviews and papers have briefly touched on the clinical implications of this cellular heterogeneity; however, there has been very little discussion on the development of study models that reflect this diversity and on multimodal therapies that could target these subpopulations. Here, we summarize the current understanding of the origins of intratumoral heterogeneity in breast cancer subtypes, and its implications for tumor progression, metastatic potential, and treatment regimens. We also discuss the advantages and disadvantages of utilizing specific breast cancer models for research, including in vitro monolayer systems and three-dimensional mammospheres, as well as in vivo murine models that may have the capacity to encompass this heterogeneity. Lastly, we summarize some of the current advancements in the development of multitarget therapeutics that have shown promising results in clinical and preclinical studies when used alone or in combination with traditional regimens of surgery, chemotherapy, and/or radiation.

Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

“…Since the activation of a pro-apoptotic response by chemotherapy can be affected by several factors, including cancer phenotypes and specific gene mutations, ultimately affecting the therapy success, the induction of alternative cell death pathway, alone or coupled to the apoptotic one [191], could represent an attractive goal in future anticancer intervention, especially in metastatic breast cancer cells [192,193]. The recent discovery of crosstalk connection among different cell death effectors and signalling pathways [194][195][196] will in fact offer novel effective therapeutic opportunities for targeted cancer therapies [197].…”

Upregulating MMP‑1 in carcinoma‑associated fibroblasts reduces the efficacy of Taxotere on breast cancer synergized by Collagen IV

“…Breast cancer is a complex disease, involving tumor cells themselves and the tumor microenvironment, which includes multiple components of the extracellular matrix (ECM), such as collagen, as well as cellular components, such as fibroblasts (19,20). Many investigations have shown that CAFs play an important role in tumor initiation, progression, apoptosis and chemotherapy resistance (19,21,22).…”

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy

“…In a murine breast cancer model, TGF-beta exposure also enhances normal lung’s ability to better support establishment of breast cancer metastases 80. TGF-beta drives breast cancer’s EMT and various biochemical, morphological, and behavioral changes characteristic of EMT 10,81–83. The manifold paths by which TGF-beta signaling leads to or enhances EMT specifically in breast cancer were outlined by Tan et al,18 Chen et al,81 Nooshinfar et al,84 and Felipe Lima et al75…”